

FILE

PTO/SB/08A (10-01)  
Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 3

**Complete if Known**

Application Number	09/990,940
Filing Date	November 21, 2001
First Named Inventor	Tian, Hui, et. al.
Art Unit	1645 1646
Examiner Name	Not yet assigned
Attorney Docket Number	018781-007410US

TECH CENTER 1600/2000

APR 01 2003

RECEIVED

**U.S. PATENT DOCUMENTS**

Examiner	Cite No. <sup>1</sup>	Document Number Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
CU	AA	US-6,033,872	03/07/2000	Bergsma et al.	
	AB	US-6,221,613	04/24/2001	Salon et al.	
	AC	US-6,221,616	04/24/2001	Salon et al.	
	AD	US-6,291,195	09/18/2001	Salon et al.	
CU	AE	US-6,362,326	03/26/2002	Sathe et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Country Code <sup>4</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	AF	JP	2001-245666		09/11/2001			
CU	AG	PCT	WO 98/46620	A1	10/22/1998	Millennium Pharm.		
	AH	PCT	WO 99/28492	A1	06/10/1999	Smithkline Beecham		
	AI	PCT	WO 00/00515	A2	01/06/2000	Hyseq, Inc.		
	AJ	PCT	WO 00/11015	A1	03/02/2000	Alphagene, Inc.		
	AK	PCT	WO 00/15793	A2	03/23/2000	Incyte Pharm.		
	AL	PCT	WO 00/22129	A1	04/20/2000	Arena Pharm.		
	AM	PCT	WO 00/22131	A2	04/20/2000	Behan et al.		
	AN	PCT	WO 00/31258	A2	06/02/2000	Arena Pharm.		
	AO	PCT	WO 00/40725	A1	07/13/2000	Takeda Chemical	Abstract in English	
	AP	PCT	WO 00/49046	A1	08/24/2000	Takeda Chemical	Abstract in English	
	AQ	PCT	WO 00/49170	A1	08/24/2000	Smithkline Beecham		
	AR	PCT	WO 00/70347	A1	11/23/2000	Trazeneca AB		
	AS	PCT	WO 00/75166	A1	12/14/2000	Univ. of California		
	AT	PCT	WO 00/78809	A1	12/28/2000	Smithkline Beecham		
	AU	PCT	WO 01/05947	A1	01/25/2001	Merck & Co.		
	AV	PCT	WO 01/07606	A1	02/01/2001	Smithkline Beecham		
	AW	PCT	WO 01/07611	A2	02/01/2001	Genetech, Inc.		
	AX	PCT	WO 01/16316	A1	03/08/2001	Takeda Chemical	Abstract in English	
	AY	PCT	WO 01/18206	A1	03/15/2001	Lexicon Genetics Inc.		
	AZ	PCT	WO 01/21577	A2	03/29/2001	Takeda Chemical		
	AAA	PCT	WO 01/36471	A2	05/25/2001	Arena Pharm.		
CU	ABB	PCT	WO 01/36479	A1	05/25/2001	Merck & Co. Banyu Pharm.		

Examiner  
Signature

Class M. K.


Date  
Considered

10/7/03

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Applicant's unique citation designation number (optional). <sup>3</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231  
SF 1439932 v1



PTO/SB/08A (10-01)  
Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/01-10

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **2**

of **3**

### Complete if Known

Application Number	09/990,940
Filing Date	November 21, 2001
First Named Inventor	Tian, Hui, et. al.
Art Unit	1645 1646
Examiner Name	Not yet assigned
Attorney Docket Number	018781-007410US

TECH CENTER 1600/2900

APR 01 2003

RECEIVED

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
Cu	ACC	PCT	WO 01/48015	A2	07/05/2001	Pharmacia & Upjohn		
	ADD	PCT	WO 01/48188	A1	07/05/2001	Helix Research	Abstract in English	
	AEE	PCT	WO 01/48189	A1	07/05/2001	Helix Research	Abstract in English	
	AFF	PCT	WO 0153455	A2	07/26/2001	Hysec, Inc.		
	AGG	PCT	WO 01/62797	A2	08/30/2001	Pharmacia & Upjohn		
	AHH	PCT	WO 01/68706	A1	09/20/2001	Merck & Co.		
	All	PCT	WO 01/70975	A1	09/27/2001	Yamanouchi Pharm.	Abstract in English	
	AJJ	PCT	WO 01/96400	A2	12/20/2001	Millennium Pharm.		
	AKK	PCT	WO 02/04518	A2	01/17/2002	Bayer Corp.		
	ALL	PCT	WO 02/10387	A2	02/07/2002	Incyte Genomics		
	AMM	PCT	WO 02/28901	A2	04/11/2002	Millennium Pharm.		
Cu	ANN	PCT	WO 02/31145	A1	04/18/2002	Takeda Chemical	Abstract in English	

Examiner  
Signature

*Clara M. Kery*

Date  
Considered

10/7/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231  
SF 1439932 v1

**Complete if Known**

Application Number	09/990,940
Filing Date	November 21, 2001
First Named Inventor	Tian, Hui, et. al.
Art Unit	4645-1646
Examiner Name	Not yet assigned
Attorney Docket Number	018781-007410US

Sheet 3 of 3

IECF CENTER 1600/2900

APR 01 2003

RECEIVED

[illegible]

Clouds - by

10/7/5

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.